Manganese ortho tetrakis (N-n-butoxyethylpyridinium-2-yl) 
Introduction
Therapeutic potential of metalloporphyrin-based mimics of superoxide dismutase (SOD) enzyme has been well documented [1] [2] [3] [4] [5] . Briefly, a true SOD mimic should be able to dismutate superoxide (i.e. oxidize or reduce O 2
• -) at a catalytic rate, k cat (O 2 NHE) [6] [7] . Over the last 15 years, a rational approach to the design of potential SOD mimics led to the development of several manganese porphyrin complexes (MnPs) with unique electronic properties and high reactivity towards O 2 • -, but also other reactive species such as peroxynitrite, ONOO - [2] [3] [4] [5] . Indeed, a structure-activity relationship (half-wave reduction potential, E 1/2 , vs. log k cat (O 2 • -)) has been developed and found to be valid for any other class of SOD mimics as well [1] .
Recent efforts have been directed towards increasing the bioavailability and reducing the toxicity of MnPs. The original structure of a potent first-generation SOD mimic, manganese ortho tetrakis(Nethylpyridinium-2-yl)porphyrin (MnTE-2-PyP 5+ ) was modified via lengthening the alkyl chains of pyridyl substituents, yielding the more lipophilic compound, the manganese ortho tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (MnTnHex-2-PyP 5+ ) [8] . This second-generation compound showed much higher brain and mitochondrial distribution than MnTE-2-PyP 5+ , but was also found to be toxic at higher concentrations and could have a potentially limited use [9] [10] . The third-generation compound, manganese ortho tetrakis(N-nbutoxyethylpyridinium-2-yl)porphyrin (MnTnBuOE-2-PyP 5+ ), was designed via introduction of oxygen atoms into the alkyl chains on the pyridyl substituents. This compound preserved high redox-activity and lipophilicity but exhibited significantly reduced toxicity relative to MnTnHex-2-PyP 5+ [11] . 
, as well as lipophilicities (distribution between n-octanol and water, log P OW ) is given in Table 1 . Comprehensive studies on bioavailability of these compounds have been performed recently as well [17] [18] [19] , in order to gain further insight into the biodistribution of MnPs, but also provide guidelines for proper dosing regimens. After assessing preliminary efficacy and toxicity data, the porphyrins were administered to mice intraperitoneally (ip) or intravenously (iv) at following doses: 10 mg/kg of MnTE-2-PyP 5+ (ip) and 2 mg/kg of MnTnBuOE-2-PyP 5+ (iv). Drug levels in plasma and different organs were followed during at least 24 hours after a single dose, thus allowing the calculation of relevant pharmacokinetic (PK) parameters via non-compartmental analysis of PK curves.
These studies showed the highest MnP bioavailability in liver (maximum concentration, C max , values of 8.1 and 13.1 µmol per L of tissue homogenate for MnTE-2-PyP 5+ and MnTnBuOE-2-PyP 5+ , respectively) and kidney, followed by spleen, lung and heart, whereas lower levels were found in plasma and lowest in the brain. Remarkably, MnTnBuOE-2-PyP 5+ has 8-fold higher brain bioavailability (expressed as the area under PK curve, AUC, divided by dose) than the less lipophilic MnTE-2-PyP 5+ (Figure 1 ), which may be highly significant for its potential application as a brain tumor radio-and chemo-therapeutic [20] [21] . MnTnBuOE-2-PyP 5+ represents the latest generation of redox-active compounds and is currently undergoing preclinical exploration. This work is intended to complement the already extensive research of its chemical and biological properties by a simple electrochemical study.
Experimental
The investigated metalloporphyrin, Mn III TnBuOE-2-PyPCl 5 was synthesized according to the published procedure [11] . Stock solution was prepared by dissolution of purified and characterized solid (known molar absorbance coefficient, ε 456 (MnTnBuOE-2-PyP 5+ ) = 1.78 × 10 5 M -1 cm -1
) [11] . Cyclic voltammetry of buffered and deaerated solutions was performed as reported in a previous study [26] . All potentials are reported vs. the normal hydrogen electrode (NHE), using the known potential of MnTE-2-PyP 5+ , E 1/2 = + 228 mV vs. NHE at pH 7.8, as a reference [11, [27] [28] .
Results and Discussion
Cyclic voltammograms of the aqueous solutions of Mn III Ps can show two distinct electron transfers: only one current peak pair attributed to the Mn III P/Mn II P redox couple is observed in a neutral or mildly basic medium (pH = 7.8, Figure 2) , whereas in the more basic medium an additional current peak pair attributed to the Mn IV P/Mn III P redox couple appears at more positive potentials (pH = 11, Figure 2 ). The cathodic and anodic current peak potentials, E pc and E pa , of both redox couples shift toward more negative values upon the increased pH of the solution. The cathodic-anodic peak separation, ΔE p = |E pc -E pa | for both redox processes is larger than 59 mV even at the scan rate of 0.02 V s -1 , indicating quasi-reversible electron transfer processes. [15, 26, 29] . These results are in agreement with the previously established scheme of behavior of MnPs in aqueous solutions [26, 30] . At pH = 7.8 only a single-electron reduction of Mn III P can be observed, shown by eq. (1), whereas at pH = 11 the single-electron reduction of Mn IV P is accompanied by a simultaneous dissociation of two protons, according to eq. (2). The latter electron transfer cannot be observed in a neutral medium due to a formal potential more positive than that of water (E 
Conclusions
Considerable interest in the impact of oxidative stress on cellular function prompted an intensive search for natural and synthetic antioxidants. High bioavailability of MnTnBuOE-2-PyP 5+ , coupled with its exceptional physicochemical properties as a redox-active ROS/RNS scavenger, makes it a promising candidate in the ongoing cancer and radioprotection preclinical studies.
